Consistent with these observations, we showed that all three E2F activators, E2F1, E2F2 and E2F3a, are highly deregulated in Her2+ breast cancer cells [18] while Wu et al. demonstrated E2F3a up-regulation in primary mouse or human tumors with amplified Her2/ERBB2 [17]. Here, ERBB2 is linked to breast carcinoma.